SCHEMBL25330872

SCHEMBL25330872

CC(CO)(NC(=O)CCl)c1ccc(Br)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
RECQL P46063 1/20 0.36
FPR2 P25090 1/20 0.36
OGG1 O15527 1/20 0.36
PDE2A O00408 3/20 0.36
MAPK1 P28482 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1173215 0.82 GAA (0.39) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL1172988 0.82 GAA (0.39) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL361630 0.82 GAA (0.39) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL730584 0.82 ALDH1A1 (0.47) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL1173300 0.77 ALDH1A1 (0.36) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL1173178 0.77 ALDH1A1 (0.36) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL1173180 0.77 ALDH1A1 (0.36) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL24856162 0.76 HDAC3 (0.41) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL361647 0.74 ACP1 (0.40) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL1048728 0.74 AR (0.38) LMNARAB9AALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2025-04-17 US disclosed
EP-4466072-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS Almac Discovery Limited (GB) 2024-11-27 EP disclosed
CN-118946566-A Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors 阿尔麦克探索有限公司 2024-11-12 CN disclosed
WO-2023139241-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, SENP7 LMNA 3424/4885MEN1 2593/4885KMT2A 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.